The approval follows October 2024's indication extension for daratumumab-VRd for newly diagnosed patients eligible for ASCT.

Marc Raab, MD, PhD, discussed the MajesTEC-5 trial of teclistamab plus standard myeloma therapies in transplant-eligible newly diagnosed multiple myeloma.

The addition of subcutaneous daratumumab to triplet therapy improved outcomes for certain patients with newly diagnosed ...

Halozyme (HALO) announced that Janssen-Cilag International, a Johnson & Johnson (JNJ) company, received European Commission approval for an ...

The European Commission (EC) has approved an indication extension of Darzalex (daratumumab) subcutaneous (SC) formulation in ...

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved an indication extension of DARZALEX® (daratumumab) subcutaneous (SC) ...

The study highlights the importance of including patient self-assessment—and not just clinician assessment—when planning ...

Daratumumab, hyaluronidase-fihj; 1800mg/30000units; per vial; soln for SC inj; preservative-free. Daratumumab binds to CD38 and inhibits the growth of CD38 expressing tumor cells by inducing ...

DARZALEX (daratumumab) is a prescription medication used to treat multiple myeloma, a type of blood cancer. It is not a chemotherapy drug but a human IgG1k monoclonal antibody that binds strongly ...

During a live event, Patrick Moore, MD, discussed the KarMMa-3 subgroup analyses and quality of life for patients with ...